We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients (DTIC)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00553618
First Posted: November 5, 2007
Last Update Posted: November 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Louisville
Information provided by (Responsible Party):
James Graham Brown Cancer Center
November 1, 2007
November 5, 2007
November 7, 2017
August 2007
August 2022   (Final data collection date for primary outcome measure)
Relapse-free survival [ Time Frame: The study duration is projected to be approximately 9 years ]
Relapse-free survival [ Time Frame: The study duration is projected to be approximately 4 years. ]
Complete list of historical versions of study NCT00553618 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma
The purpose of this study is to see if the combination of the two cancer drugs, Dacarbazine (DTIC) and a low-dose of Proleukin (IL2), would provide a less toxic and more effective treatment for melanoma than currently available treatments for people with high-risk melanoma. Dacarbazine (DTIC) and Proleukin (IL2) are both FDA-approved drugs for the treatment of melanoma.

The prognosis of patients with malignant melanomas that are greater than 4 mm deep or involve regional lymph nodes is poor, even after successful surgical removal. The concept of adjuvant therapy for melanoma is derived from the hypothesis that these therapies may kill micro-metastatic seeds of melanoma cells.

The rationale for this particular drug combination regimen is that melanoma cells may act as a vaccine from which to generate melanoma-specific T cell expansion by way of IL2 administration. In unpublished results, forty-two stage II and III melanoma patients were treated with this regimen at the University of Alabama with IRB approval. Analysis of relapse free survival and overall survival in patients treated with this combination suggested a small improvement in disease-free survival when compared to historical controls or another study whose patients had similar but not identical staging (median follow-up time of 30 months). Importantly, no unanticipated side effects were observed as a result of the combination of these two drugs (both of which are FDA-approved for use in melanoma patients).

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Metastatic Melanoma
Drug: Proleukin and Dacarbazine

IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.

Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks.

Other Name: Proleukin, Dacarbazine
Experimental: Proleukin/DTIC Arm
Adjucant proleukin and DTIC
Intervention: Drug: Proleukin and Dacarbazine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
160
August 2022
August 2022   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must fulfill one of the following criteria:
  • T4 NO MO - Deep primary melanoma (> 4.0 mm) with or without lymphadenectomy.
  • T1-4 N1-3 MO - Primary melanoma with regional lymph node metastases found at lymphadenectomy or sentinel lymph node sampling, but clinically undetectable (occult).
  • T1-4 N1-3 MO - Primary melanoma with clinically apparent (overt) regional lymph node metastases confirmed by lymphadenectomy.
  • T1-4 N1-3 MO - Recurrence of melanoma at the proximal regional lymph node(s).
  • Patients must have undergone a wide excision of the primary and, if >1mm in depth, have completed sentinel lymph node sampling or lymphadenectomy as is standard of practice. Patients must have confirmation of adequate surgical margins around the primary lesion (1 or 2 cm minimum, for primary lesions of 1-2 mm depth; 2 cm for primary lesions equal to or greater than 2 mm depth). When entering this study with recurrent regional lymph node disease, the patient must be enrolled no later than 90 days from the date of lymphadenectomy.
  • For subungual melanomas a distal interphalangeal. amputation is required. For patients with regional lymph node recurrence, the same evidence for adequate margins around the primary are required as for patients at initial presentation.
  • For safety reasons, patients must be of age between 18 and 85.
  • Patients must have ECOG performance status 0-2.
  • Patients must have WBC >3,000, platelet count >100,000, and hematocrit >33.
  • Patients must have SGOT and bilirubin <2x normal; creatinine <2.3; BUN <33.
  • Patients must have no active medical or psychiatric disorders requiring therapy that would prevent completion of the protocol.
  • Patients must give written informed consent.

Exclusion Criteria:

  • Patients for whom histopathologic examination of the primary or metastatic melanoma is not positive are ineligible.
  • Patients who have clinical, radiological, laboratory, or pathological evidence of incompletely resected melanoma or any distant metastatic disease are ineligible.
  • Patients with an active second cancer (except in situ cervical cancer, or basal or squamous skin cancer) are ineligible. Exceptions may be discussed with the principal investigator.
  • Patients with organic brain syndrome or significant impairment of basal cognitive function or any psychiatric disorder that might preclude participation in the full protocol, are ineligible.
  • Patients who have had prior adjuvant chemotherapy, immunotherapy, including preoperative infusion or perfusion therapy are ineligible.
  • Patients with recurrent melanoma at regional lymph nodes must not have been previously entered into this study.
  • Patients with more than one lymph node group involved are ineligible.
  • Women of child bearing age who are not on adequate birth control are ineligible.
  • Women who are pregnant or breast feeding are ineligible.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00553618
07.0008
Yes
Not Provided
Not Provided
James Graham Brown Cancer Center
James Graham Brown Cancer Center
University of Louisville
Principal Investigator: Jason A Chesney, MD James Graham Brown Cancer Center, University of Louisville
James Graham Brown Cancer Center
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP